{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-21-139573","form_type":"8-K","ticker":"ACXP","cik":"0001736243","company_name":"Acurx Pharmaceuticals, Inc.","filed_at":"2021-11-16T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.888820+00:00","generated_at":"2026-06-28T07:50:34.470652+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Acurx Pharma Q3 net loss $4.6M; Phase 2b enrollment underway","bullets":["Net loss of $4.6M ($0.46/diluted share) for Q3 2021 vs. $1.3M ($0.21) in Q3 2020.","Cash balance $14.5M as of Sep 30, 2021; R&D spend $1.1M (up from $0.7M) on Phase 2b costs.","Phase 2b trial for C. difficile infection (ibezapolstat) enrollment started; completion expected Q3 2022.","Phase 2a data showed 100% clinical cure, 100% sustained cure, beneficial microbiome changes.","New collaboration with Leiden University to study DNA pol IIIC enzyme mechanism of action."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-21-139573","json":"https://secwatch.observer/filing/0001104659-21-139573.json","markdown":"https://secwatch.observer/filing/0001104659-21-139573.md","text":"https://secwatch.observer/filing/0001104659-21-139573.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1736243/000110465921139573/0001104659-21-139573-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1736243/000110465921139573/tm2133025d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T07:50:34.470652+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}